Ratings for Y-mAbs Therapeutics (NASDAQ:YMAB) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
0
Last 30D
1
0
0
0
0
1M Ago
2
1
0
0
0
2M Ago
0
0
0
0
0
3M Ago
0
0
0
0
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.75, a high estimate of $26.00, and a low estimate of $21.00. Marking an increase of 35.71%, the current average surpasses the previous average price target of $17.50.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Y-mAbs Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Robert Burns
HC Wainwright & Co.
Raises
Buy
$22.00
$21.00
Bill Maughan
Canaccord Genuity
Raises
Buy
$26.00
$22.00
Etzer Darout
BMO Capital
Raises
Outperform
$26.00
$16.00
Robert Burns
HC Wainwright & Co.
Raises
Buy
$21.00
$11.00
Key Insights:
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Y-mAbs Therapeutics. This ...Full story available on Benzinga.com
Benzinga
